Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) insider Sandra L. Hatten bought 2,100 shares of the company’s stock in a transaction dated Thursday, September 14th. The stock was bought at an average cost of $9.36 per share, with a total value of $19,656.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Avadel Pharmaceuticals PLC. (NASDAQ AVDL) traded up 4.09% during trading on Wednesday, hitting $11.19. 121,937 shares of the stock were exchanged. Avadel Pharmaceuticals PLC. has a 52 week low of $8.14 and a 52 week high of $13.25. The firm has a 50 day moving average price of $9.30 and a 200 day moving average price of $9.78. The firm has a market capitalization of $448.54 million, a P/E ratio of 12.16 and a beta of 1.47.

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.14. Avadel Pharmaceuticals PLC. had a return on equity of 29.84% and a net margin of 21.13%. The business had revenue of $46.30 million for the quarter, compared to analyst estimates of $45.17 million. The firm’s revenue for the quarter was up 19.0% compared to the same quarter last year. Analysts forecast that Avadel Pharmaceuticals PLC. will post $1.16 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was first published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/flamel-technologies-s-a-avdl-insider-sandra-l-hatten-purchases-2100-shares-of-stock/1567268.html.

AVDL has been the topic of a number of analyst reports. Langenberg & Company reiterated a “buy” rating and issued a $30.00 price target (up from $27.00) on shares of Avadel Pharmaceuticals PLC. in a research report on Thursday, September 7th. Zacks Investment Research downgraded Avadel Pharmaceuticals PLC. from a “hold” rating to a “sell” rating in a research report on Monday, August 7th. Roth Capital set a $15.00 price objective on Avadel Pharmaceuticals PLC. and gave the company a “buy” rating in a research report on Wednesday, August 9th. Finally, Ladenburg Thalmann Financial Services boosted their price objective on Avadel Pharmaceuticals PLC. from $27.00 to $30.00 in a research note on Thursday, September 7th.

Hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. acquired a new stake in shares of Avadel Pharmaceuticals PLC. in the 1st quarter valued at approximately $3,654,000. US Bancorp DE bought a new stake in shares of Avadel Pharmaceuticals PLC. during the 1st quarter valued at approximately $121,000. Acadian Asset Management LLC grew its holdings in shares of Avadel Pharmaceuticals PLC. by 9.7% during the 2nd quarter. Acadian Asset Management LLC now owns 1,672,207 shares of the company’s stock valued at $18,444,000 after purchasing an additional 147,907 shares during the last quarter. State of New Jersey Common Pension Fund D grew its holdings in shares of Avadel Pharmaceuticals PLC. by 27.9% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 42,090 shares of the company’s stock valued at $464,000 after purchasing an additional 9,175 shares during the last quarter. Finally, Sei Investments Co. grew its holdings in shares of Avadel Pharmaceuticals PLC. by 29.5% during the 2nd quarter. Sei Investments Co. now owns 12,726 shares of the company’s stock valued at $140,000 after purchasing an additional 2,900 shares during the last quarter. 69.09% of the stock is owned by hedge funds and other institutional investors.

About Avadel Pharmaceuticals PLC.

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Insider Buying and Selling by Quarter for Avadel Pharmaceuticals PLC. (NASDAQ:AVDL)

Receive News & Ratings for Avadel Pharmaceuticals PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.